<SEC-DOCUMENT>0001299933-14-001548.txt : 20141008
<SEC-HEADER>0001299933-14-001548.hdr.sgml : 20141008
<ACCEPTANCE-DATETIME>20141007211349
ACCESSION NUMBER:		0001299933-14-001548
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20141007
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20141008
DATE AS OF CHANGE:		20141007

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			STEMCELLS INC
		CENTRAL INDEX KEY:			0000883975
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				943078125
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19871
		FILM NUMBER:		141146637

	BUSINESS ADDRESS:	
		STREET 1:		3155 PORTER DRIVE
		STREET 2:		.
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94304
		BUSINESS PHONE:		6504753100

	MAIL ADDRESS:	
		STREET 1:		3155 PORTER DRIVE
		STREET 2:		.
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94304

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CYTOTHERAPEUTICS INC/DE
		DATE OF NAME CHANGE:	19930328
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>htm_50612.htm
<DESCRIPTION>LIVE FILING
<TEXT>
<!-- CoverPageHeader start -->
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 3.2//EN">
<HTML>
<HEAD>
<TITLE> StemCells, Inc. (Form: 8-K) </TITLE>
</HEAD>
<BODY TEXT="#000000" BGCOLOR="#FFFFFF" ALINK="#0000FF" HLINK="#FF0000" VLINK="#800080">
<!-- Comment1 -->
<A NAME="DOCUMENT_TOP">&nbsp;</A>
<P>
<!-- CoverPageHeader end --><!-- CoverPageTitle START -->
<A NAME="DOCUMENT_TOP">&nbsp;</A>
<HR NOSHADE>
<P>
<P ALIGN="CENTER">
<FONT SIZE="4">
		UNITED STATES<BR>
	SECURITIES AND EXCHANGE COMMISSION
</FONT>
<BR>
<FONT SIZE="2">
	WASHINGTON, D.C. 20549
</FONT>
<P ALIGN="CENTER">
<FONT SIZE="5">
	FORM 8-K
</FONT>
<FONT SIZE="2">

</FONT>
</P>
<P ALIGN="CENTER">
<FONT SIZE="3">
	CURRENT REPORT
</FONT>
</P>
<P ALIGN="CENTER">
<FONT SIZE="2">
	Pursuant to Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934
</FONT>
</P>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="BOTTOM">
<TD WIDTH="51%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="44%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Date of Report (Date of Earliest Event Reported):
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	October 7, 2014
</FONT>
</TD>
</TR>
</TABLE>
<BR>
</CENTER>
<!-- CoverPageTitle END --><!-- CoverPageRegistrant START -->
<P ALIGN="CENTER"><!-- -->
<FONT SIZE="6">
	StemCells, Inc.
</FONT>
<FONT SIZE="2">
<BR>__________________________________________<BR>
	(Exact name of registrant as specified in its charter)
</FONT>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="BOTTOM">
<TD WIDTH="33%">
	&nbsp;
</TD>
<TD WIDTH="34%">
	&nbsp;
</TD>
<TD WIDTH="33%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Delaware
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	000-19871
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	94-3078125
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
_____________________<BR>
	(State or other jurisdiction
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
_____________<BR>
	(Commission
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
______________<BR>
	(I.R.S. Employer
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	of incorporation)
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	File Number)
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Identification No.)
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	7707 Gateway Blvd, Suite 140, Newark, California
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	94560
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
_________________________________<BR>
	(Address of principal executive offices)
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
___________<BR>
	(Zip Code)
</FONT>
</TD>
</TR>
</TABLE>
</CENTER>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">

<TR VALIGN="BOTTOM">
<TD WIDTH="51%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="44%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Registrant&#146;s telephone number, including area code:
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	510.456.4000
</FONT>
</TD>
</TR>
</TABLE>
</CENTER>
<P ALIGN="CENTER">
<FONT SIZE="2">
	Not Applicable
<BR>______________________________________________<BR>
	Former name or former address, if changed since last report
</FONT>
<P ALIGN="CENTER">
<FONT SIZE="2">
	&nbsp;
</FONT>
<!-- CoverPageRegistrant END --><P><FONT SIZE="2">
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any
of the following provisions:</FONT>
</P>
<P><FONT SIZE="2">
[&nbsp;&nbsp;]&nbsp;&nbsp;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<br>
[&nbsp;&nbsp;]&nbsp;&nbsp;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<br>
[&nbsp;&nbsp;]&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<br>
[&nbsp;&nbsp;]&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<br>
</P></FONT><!-- PageBreak START -->
<P>
<HR NOSHADE>
<DIV ALIGN="LEFT" STYLE="PAGE-BREAK-BEFORE:ALWAYS">
<A HREF="#DOCUMENT_TOP">
<U>
<B>
<FONT SIZE="2">Top of the Form</FONT>
</B>
</U>
</A>
</DIV>
<!-- PageBreak END --><!-- Item START -->
<P ALIGN="LEFT">
<FONT SIZE="2">
<B>
	Item 8.01 Other Events.
</B>
</FONT>
</P>
<P ALIGN="LEFT">
<FONT SIZE="2">
On October 7, 2014, StemCells, Inc. (the "Company") issued a press release announcing the initiation of its Pathway Study, a Phase II proof of concept clinical trial using the Company's proprietary HuCNS-SC platform of human neural stem cells for the treatment of cervical spinal cord injury.  <br><br>A copy of this press release is attached hereto as Exhibit 99.1.
</FONT>
</P>
<!-- Item END -->
<BR><BR><BR><BR><!-- Item START -->
<P ALIGN="LEFT">
<FONT SIZE="2">
<B>
	Item 9.01 Financial Statements and Exhibits.
</B>
</FONT>
</P>
<P ALIGN="LEFT">
<FONT SIZE="2">
(d) Exhibit<br><br>Exhibit 99.1 Press release dated October 7, 2014 announcing initiation of the Company's Phase II clinical trial in spinal cord injury.
</FONT>
</P>
<!-- Item END -->
<BR><BR><BR><BR><P ALIGN="LEFT" STYLE="FONT-SIZE: 10PT"></P><!-- PageBreak START -->
<P>
<HR NOSHADE>
<DIV ALIGN="LEFT" STYLE="PAGE-BREAK-BEFORE:ALWAYS">
<A HREF="#DOCUMENT_TOP">
<U>
<B>
<FONT SIZE="2">Top of the Form</FONT>
</B>
</U>
</A>
</DIV>
<!-- PageBreak END --><!-- SignatureHeader START -->
<P ALIGN="CENTER">
<FONT SIZE="2">
<B>
	SIGNATURES
</B>
</FONT>
</P>
<P ALIGN="LEFT">
<FONT SIZE="2">
	Pursuant to the requirements of the Securities Exchange Act of 1934, the
	registrant has duly caused this report to be signed on its behalf by the
	undersigned hereunto duly authorized.
</FONT>
</P>
<!-- SignatureHeader END --><!-- Signature START -->
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="BOTTOM">
<TD WIDTH="19%">
	&nbsp;
</TD>
<TD WIDTH="34%">
	&nbsp;
</TD>
<TD WIDTH="3%">
	&nbsp;
</TD>
<TD WIDTH="1%">
	&nbsp;
</TD>
<TD WIDTH="43%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" VALIGN="TOP" ALIGN="LEFT">
<FONT SIZE="2">
	StemCells, Inc.
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
<I>
	October 8, 2014
</I>
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	By:
</I>
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	Kenneth Stratton
</I>
<BR>
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<HR SIZE="1" NOSHADE>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	Name: Kenneth Stratton
</I>
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	Title: General Counsel
</I>
</FONT>
</TD>
</TR>
</TABLE>
</CENTER>
<!-- Signature END --><!-- PageBreak START -->
<P>
<HR NOSHADE>
<DIV ALIGN="LEFT" STYLE="PAGE-BREAK-BEFORE:ALWAYS">
<A HREF="#DOCUMENT_TOP">
<U>
<B>
<FONT SIZE="2">Top of the Form</FONT>
</B>
</U>
</A>
</DIV>
<!-- PageBreak END --><P ALIGN="CENTER">
<FONT SIZE="2">
	Exhibit&nbsp;Index
</FONT>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="60%">
<TR VALIGN="BOTTOM">
<TD WIDTH="8%">
	&nbsp;
</TD>
<TD WIDTH="15%">
	&nbsp;
</TD>
<TD WIDTH="77%">
	&nbsp;
</TD>
</TR>

<BR>
<TR VALIGN="BOTTOM">
<TD NOWRAP ALIGN="LEFT">
<FONT SIZE="1">
<B>
	Exhibit No.
</B>
</FONT>
</TD>
<TD>
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP ALIGN="LEFT">
<FONT SIZE="1">
<B>
	Description
</B>
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD NOWRAP ALIGN="CENTER">
<HR SIZE="1" NOSHADE>
</TD>
<TD>
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP ALIGN="CENTER">
<HR ALIGN="LEFT" SIZE="1" WIDTH="88%" NOSHADE>
</TD>
</TR>





<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" WIDTH="8%" nowrap>
<FONT SIZE="2">
<DIV ALIGN="LEFT">
	99.1
</DIV>
</FONT>
</TD>
<TD WIDTH="15%">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP" WIDTH="77%">
<FONT SIZE="2">
Press release dated October 7, 2014
</FONT>
</TD>
</TR></TABLE></CENTER><!-- HTMLFooter START -->
</BODY>
</HTML>
<!-- HTMLFooter END -->
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 3.2//EN">
<HTML>
<HEAD>
<TITLE> EX-99.1 </TITLE>
</HEAD>
<BODY TEXT="#000000" BGCOLOR="#FFFFFF" ALINK="#0000FF" HLINK="#FF0000" VLINK="#800080">

<BODY style="font-family: 'Times New Roman',Times,serif">


<P align="center" style="font-size: 10pt"><FONT style="font-size: 12pt"><B>StemCells, Inc. Initiates Phase II Clinical Trial in Cervical Spinal Cord Injury</B></FONT>



<P align="center" style="font-size: 12pt"><I>First study assessing efficacy of neural stem cells for the treatment of cervical spinal cord injury</I>



<P align="center" style="font-size: 12pt"><I><img src="e40474-14280171748324b978_2.jpg"></I>



<P align="left" style="font-size: 12pt"><FONT style="font-size: 10pt"><B>NEWARK, CA, October&nbsp;7, 2014 </B>(GLOBE NEWSWIRE) &#151; StemCells, Inc. (Nasdaq:STEM) a world leader in
the research and development of cell based therapies for the treatment of disorders of the central
nervous system announced today that it has initiated its Pathway<sup>&#174;</sup> Study a Phase II proof
of concept clinical trial using its proprietary HuCNS-SC<sup>&#174; </sup>platform of human neural stem
cells for the treatment of cervical spinal cord injury (SCI). Approximately 1.3&nbsp;million people in
the United States, report being paralyzed due to a SCI, and there currently are no effective
treatments available. Approximately 56% of the spinal cord injuries occur in the cervical region.
Overall, approximately 13% of SCI patients have no mobility and 35% have limited mobility after the
traumatic injury.<sup>1 </sup>
</FONT>

<P align="left" style="font-size: 10pt">The Pathway Study is the first clinical study designed to evaluate both the safety and efficacy of
transplanting stem cells into patients with traumatic injury to the cervical spinal cord. The trial
will be conducted as a randomized, controlled, single-blind study and efficacy will be primarily
measured by assessing motor function according to the International Standards for Neurological
Classification of Spinal Cord Injury (ISNCSCI). The primary efficacy outcome will focus on change
in upper extremity strength as measured in the hands, arms, and shoulders. The trial will follow
the patients for one year from the time of enrollment.


<P align="left" style="font-size: 10pt">Earlier this year, the Company completed enrollment in an open-label Phase I/II clinical trial in
thoracic SCI and reported interim results from this trial on eight patients with at least six
months of follow-up post transplantation. Half of the patients transplanted had significant
post-transplant gains in sensory function. The interim results also continue to confirm the
favorable safety profile of the cells and the surgical procedure. Based upon the strength of the
interim data from its thoracic SCI study, the Company made the decision to move forward with the
first in human clinical trial to assess the efficacy of stem cell transplants for the treatment of
cervical SCI.


<P align="left" style="font-size: 10pt">&#147;The initiation of the Pathway Study represents a major milestone for StemCells, Inc. as we pursue
the development of a truly breakthrough therapy for spinal cord injury,&#148; said Martin McGlynn,
president and chief executive officer of StemCells, Inc. &#147;While we are thrilled by the prospect
that patients with thoracic level injuries might be able to regain lost sensory function below the
site of the injury, the possibility that patients with injuries to the cervical region of the cord
might regain or improve lost motor function could be truly life-changing.&#148;


<P align="left" style="font-size: 10pt">The first site initiated into the Pathway Study is the University of Miami Miller School of
Medicine, home to The Miami Project To Cure Paralysis, one of the world&#146;s most comprehensive
research centers dedicated to finding more effective treatments for, and ultimately a cure for,
paralysis.


<P align="left" style="font-size: 10pt">&#147;Our center has been a leader in clinical research aimed at curing paralysis,&#148; said Allan D. Levi,
M.D., Ph.D., F.A.C.S., Robert M. Buck Distinguished Chair in Neurological Surgery at the University
of Miami Miller School of Medicine and principle investigator for the center. &#147;I have been involved
in pioneering research efforts in applying cellular transplants to treat spinal cord injury
patients for many years, and have closely followed the pre-clinical and clinical efforts of
StemCells. We are excited to be the first site to open this important clinical trial. This is a
time of promise and hope for victims of spinal cord injuries and, should this study be successful,
it moves us one step closer to our ultimate goal of curing paralysis.&#148;


<P align="left" style="font-size: 10pt"><FONT style="font-size: 11pt"><B>About the Pathway Spinal Cord Injury Clinical Trial</B>
</FONT>

<P align="left" style="font-size: 11pt"><FONT style="font-size: 10pt">The Company&#146;s Pathway Phase II clinical trial titled &#147;Study of Human Central Nervous System
(CNS)&nbsp;Stem Cell Transplantation in Cervical Spinal Cord Injury,&#148; will evaluate the safety and
efficacy of transplanting the Company&#146;s proprietary human neural system stem cells (HuCNS-SC
cells), into patients with traumatic injury in the cervical region of the spinal cord. This is a
randomized, controlled, single-blind study with a primary endpoint of change from baseline in
ISNCSCI upper extremity motor scores. Patients will be followed for a period of twelve months post
enrollment.
</FONT>

<P align="left" style="font-size: 10pt">Information about the Company&#146;s spinal cord injury program can be found on the StemCells, Inc.
website at:


<P align="left" style="font-size: 10pt">http://www.stemcellsinc.com/Therapeutic-Programs/Spinal-Cord-Injury.htm


<P align="left" style="font-size: 10pt">Information for patients interested in participating in the study is available at the Pathway
website at:


<P align="left" style="font-size: 10pt">http://www.sciresearchstudy.com


<P align="left" style="font-size: 10pt">Additional information about the clinical trial is available at:


<P align="left" style="font-size: 10pt">http://clinicaltrials.gov/ct2/show/NCT02163876?term=stem&#043;cells&#043;cervical&#043;spinal&#043;cord&#043;injury&rank=1


<P align="left" style="font-size: 10pt"><FONT style="font-size: 11pt"><B>About HuCNS-SC Cells</B>
</FONT>

<P align="left" style="font-size: 11pt"><FONT style="font-size: 10pt">StemCells, Inc. has demonstrated human safety data from completed and ongoing clinical studies
of its proprietary HuCNS-SC cells. StemCells clinicians and scientists believe that HuCNS-SC cells
may have broad therapeutic application for many diseases and disorders of the central nervous
system (CNS). Because the transplanted HuCNS-SC cells have been shown to engraft and survive
long-term, there is the possibility of a durable clinical effect following a single
transplantation.&nbsp;The Company&#146;s preclinical research has demonstrated that HuCNS-SC cells can be
directly transplanted in the CNS with no sign of tumor formation or adverse effects. The HuCNS-SC
platform technology is a highly purified composition of human neural stem cells that are expanded
and stored as banks of cells.
</FONT>

<P align="left" style="font-size: 10pt"><FONT style="font-size: 11pt"><B>About StemCells, Inc.</B>
</FONT>

<P align="left" style="font-size: 11pt"><FONT style="font-size: 10pt">StemCells, Inc. is a world leader in the research and development of cell based therapies for
the treatment of disorders of the central nervous system. The Company&#146;s platform technology,
HuCNS-SC cells (purified human neural stem cells), is currently in clinical development as a
potential treatment for a broad range of central nervous system disorders. The Company is
conducting a Phase I/II clinical trial in chronic spinal cord injury in Switzerland, Canada and the
United States, and has reported positive interim data for the first eight patients. The Company is
also conducting a Phase I/II clinical trial in dry age-related macular degeneration (AMD)&nbsp;in the
United States, and has reported positive results on the first seven patients. In a Phase I clinical
trial in Pelizaeus-Merzbacher disease (PMD), a fatal myelination disorder in children, the Company
has shown preliminary evidence of progressive and durable donor-derived myelination in all four
patients transplanted with HuCNS-SC cells. In addition, the Company is pursuing preclinical studies
in Alzheimer&#146;s disease, with support from the California Institute for Regenerative Medicine
(CIRM). StemCells also markets stem cell research products, including media and reagents, under the
SC Proven<sup>&#174;</sup> brand. Further information about StemCells is available at .
</FONT>

<P align="left" style="font-size: 10pt"><FONT style="font-size: 8pt"><I>Apart from statements of historical fact, the text of this press release constitutes
forward-looking statements within the meaning of the U.S. securities laws, and is subject to the
safe harbors created therein. These statements include, but are not limited to, statements
regarding whether the improvements in sensory function seen in the Company&#146;s Phase I/II clinical
study of spinal cord injury will persist and whether they will prove to be clinically meaningful;
the prospect for evaluating trial patients for changes in their sensation, motor function and
bowel/bladder function; the potential of the Company&#146;s HuCNS-SC cells to treat spinal cord injury
and other central nervous system disorders; and the future business operations of the Company,
including its ability to conduct clinical trials as well as its other research and product
development efforts. These forward-looking statements speak only as of the date of this news
release. The Company does not undertake to update any of these forward-looking statements to
reflect events or circumstances that occur after the date hereof. Such statements reflect
management&#146;s current views and are based on certain assumptions that may or may not ultimately
prove valid. The Company&#146;s actual results may vary materially from those contemplated in such
forward-looking statements due to risks and uncertainties to which the Company is subject,
including the fact that additional trials will be required to demonstrate the safety and efficacy
of the Company&#146;s HuCNS-SC cells for the treatment of any disease or disorder; uncertainty as to
whether the FDA or other applicable regulatory agencies will permit the Company to continue
clinical testing in spinal cord injury or in future clinical trials of proposed therapies for other
diseases or conditions; uncertainties regarding the Company&#146;s ability to recruit the patients
required to conduct its clinical trials or to obtain meaningful results; uncertainties regarding
the Company&#146;s ability to manufacture viable cells sufficient to enroll the patients planned for the
Company&#146;s Phase II studies; uncertainties regarding the Company&#146;s ability to obtain the increased
capital resources needed to continue its current and planned research and development operations;
uncertainty as to whether HuCNS-SC cells and any products that may be generated in the future in
the Company&#146;s cell-based programs will prove safe and clinically effective and not cause tumors or
other adverse side effects; and other factors that are described under the heading &#147;Risk Factors&#148;
in the Company&#146;s Annual Report on </I><I>Form 10-K</I><I> for the year ended December&nbsp;31, 2013, and in its
subsequent reports on </I><I>Form 10-Q</I><I> and </I><I>Form 8-K</I><I>.</I>
</FONT>

<P align="left" style="font-size: 8pt">References:


<P align="left" style="font-size: 8pt">1.</FONT><FONT style="font-size: 11pt"> </FONT><FONT style="font-size: 8pt">Christopher & Dana Reeve Foundation: &#147;One Degree of Separation: Paralysis and Spinal
Cord Injury in the United States.&#148; 2009
</FONT>

<P align="left" style="font-size: 8pt"><FONT style="font-size: 10pt"><B>CONTACT: </B>Greg Schiffman
</FONT>

<P align="left" style="font-size: 10pt; text-indent: 5%">StemCells, Inc.


<P align="left" style="font-size: 10pt; text-indent: 5%">Chief Financial Officer


<P align="left" style="font-size: 10pt; text-indent: 5%">(510)&nbsp;456-4128


<P align="left" style="font-size: 10pt; text-indent: 5%">Andrea Flynn


<P align="left" style="font-size: 10pt; text-indent: 5%">Russo Partners


<P align="left" style="font-size: 10pt; text-indent: 5%">(646)&nbsp;942-5631


<P align="center" style="font-size: 10pt">#####




<P align="center" style="font-size: 10pt; display: none">




<!-- v.121908 -->
</BODY>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>e40474-14280171748324b978_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 e40474-14280171748324b978_2.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_
MVP!#`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``1"``_`.8#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#^_9G5!EOI
MP"23UP`.2>.`.3T'-`=2`0<@XZ8/7/IGTJ.XC,D3("P)##*Y##*LORD$%3SU
M!!'8CJ/B/QM\<-0_9.\8:-9_&N^N;O\`9Q\<Z_8^'_"?QNNEO;B/X)^*-49H
M--\'?'_7=1OKQK;P1XDU5[;2/A[\9]0GBL8=?U&R\`?$=K'5[CPSXO\`&>E.
ME4K2]G2BYU&GR4U\=1K5Q@OM3Y;R4+\T[.,%*347I2I3K2Y*:YIM>Y!:RF_Y
M8):RDU=J*U=FE=Z'V^WKVX'O_%_C7S5IOQ$OV_:W\2?":8HNF0?L\>!_B'IR
MO>W'FO?77Q(\?>&M7,&G/(ULT44%IH@N+RWAAGC,MI!>/<1R6*VWT?'<PSHK
MQN&4D$,`<,"`<C(&X$'`QGGCKQ7Y17?Q1M]-_P""T>F?"^YU6*V7Q%_P3G;4
MM+M'6)3>>(=-_:(U.]N+19?L[3-.?#MIJ.HQQ^?'"D%C?.\;LR&+IP.&EB/K
MO+!MT,#7Q,M'=0HJ,Y2LD[)1ZMI7]#HP="5=8I*.M+!UL0TU*Z5+E<FK+HFU
M=Z:KU/UFJ!IMIP%8\XXQT]1DK^7)]JJ7-[#:6LUU=7,=K!;Q//<3RR+'%!#&
M-TDLLDA5(XXT^>21RJ1J"[D(#7P5\/\`XAW7[</BNY\1>#;C4K']D#X<>,6M
M=(\6:?>S6/\`PU=XZ\)W4L=[+HEQ;)%/+^S9X)\1QI;'4['4(1\<_&_A^XTN
M=)_@GI&KV/QBYJ=&=2-2I\-&CRJK4^RI3_A4[_\`/RHU+EBM>6,IRM",I+GI
MTY5(U*EK4J7+SS>R<OAA;?VC=TH[V3E\*;7Z"1R+(H9<X(!!/<'H1C(.>O';
M!Z&GTR-!&,#^9/<GOW)))/4YYKRGX\_$&_\`A-\$/C#\5-+L+75=1^&GPM^(
M7C^PTJ^EF@LM3O?!GA'6/$=KI]Y-;_Z1%:WL^F);3R0?O8XI6=`64"H2;:C%
M7<FDEM=O1:O1>K,SUFBOXYO@M_P<!_\`!4+]H_PYJ?BSX!?\$S--^,GAO0];
M;PUK>O?#>S^,/BO2](\0II>F:S)HM_>Z187EO:ZFFF:SI=_]FF8-]DO[:X*^
M7*N?8C_P<0?M.?`.[M)/VZ_^"6'Q^^"_A.>>*W?QSHD?C#1K66220QI;:+I/
MQ5^'?A#PUKE_*2!'#%\4[0&147:%F##V9\/YI";I.E1E66GL(8O"SK7LG;V4
M:W/S6DGRVYM=BN6^S3\KZG]6]%?-W[*_[5OP._;+^$6@_&_]G_QQ9^-O`NN/
M=6,S+&]AKOAKQ!I[1KJOA3Q?H%R$U'PWXETKS[=Y],U&)'N=/N]/UK39=0T/
M5=+U2^^D:\><)4Y2A.,H3@W&<)*THR6\9)ZIKJA-6T84UF"C)S^'^?U[=3QF
MG5^=/[<G[=WA[]ES2;+PGX9&E>*/C3XIM3=Z)X;N9)9['PQI!?R#XH\5P6DU
MO<PVLDOFV^A:7]HMKK7+NWNFAFCL].U":#"M6AAZ52O4;5.E"4YM)MVBKM)+
M64GTBM7T0N_EJ?0WQ\_:A^$?[/&D_:O'>N[]:O+<W&C^#=&%O?\`BO68P\Z+
M-;Z6UU;_`&/3VFM;BV.L:K-8:2EW$]F;MKS9:2?(7AOQO^W'^U.J:UX2@\/?
MLN_";4H0=-\0ZQIB^*_B%J]A-`Y74-,L-4MHTGM+L/'+:77V+P>J6LGVO2M:
MU4M#<K\7_L7?\*&\>_M9W7@G]IGXM67Q"_;9U'0IOB3_`,*"UG3M=U76/!>C
M6VGZ-X@M/$GQ,N+/2'\'Z#XC&B:QH6H^&?ASJ6HZ<_AG0=3TYG\/_P!HK9:=
MX5_=/XK^(K_P/\+OB+XRT2*S?4_"'@+Q?XHTR#4(II[";4/#_AW4]5LHKV&W
MGMIY+1[FTB%Q'!<V\TD.](YXF8./SU9/Q9Q3CIUL[QV8<.</2E".69%E-6I@
M,TS.C-KDQ><YG3?UK#T,1?\`=8/`2PT_9ZUJ[39Y$\-C<;6E*O7JX/"1=J6'
MPLG2Q%;O.OBHVJ1IMJ\*-'D[RJR^$^?-*_8S\,3VUHOQ(^*OQW^+%Q";>YDC
M\4?%_P`::9HJZC$F&N;+1?">IZ!%;0_-(L5O=W&H>7`S0R33J\K2:-G^P_\`
MLVZ;<27VC^`M0T'5I9)IGUKP]\0_B9H.NO+-+:W$K-KFD^+K357W75E;W:@W
M1"72FZC"W+RRR_&?_!$[]OCXT?\`!1?]EGQY\;_CKHOPYT'Q;X:^/7BCX7Z?
M8?##0_$.@>'6\/:)\/\`X7^*[2ZN++Q/XL\9ZE)J\FH^-M5BN;E-7CM&LX-/
MBBL(9H;FYO/V'``Z5]#B/#OA7`UZF$Q7#N55L1AI>SJ5,3AZ./K^TII*[QF)
MC6Q-22M_$==SEHW)O4Z7E67K26"PU22M[]2E&K4>BUE5K*I.4M$^:Z=];GQ#
MXC_9H^+/AI&U?X%_M+?$K1=7B,K?\(U\7]2'Q=\%ZE"(V:UT[S?$UK<^(?#X
M6Y\L2:S9WNJ7HM@Z?9I)79SYI8?MI^-/@SXCTGP!^V%\-CX"N]13RM,^+/@9
M[G7/AGXBDC<+/<I9RK-K&F)`CQBZMHKC5=:@9UO;_0M(TV>&X3]*"H(((X/)
M_+%<#\0?AUX-^)WAC4?!OCGPYIOB7P[JL;1WFG:G$95!`_=7-G<(\=UI^HVS
M[9K'4[":WOK&=%GM+B"95D'BYGPGCL%&6*X,S6MDN.IKGAEN*JU<;P[BW%QY
M:&(R^O*M4P$*C4HO$Y14P=2FY*<XU8QE"6%;+ZM/FJY;B)X6MI:C5G.O@II-
M>Y*A*7[KF2LIT'!Q?O.,[6.@\/\`B/0?%6DZ=KOAO5].UW1=6M(KW2]7TF^M
MM1TS4+20#9<6=W:236\\+G@/&[`$8.,5OKT]\G/US7X+Z_%\:?\`@F?\1X[W
MPW)>>/?V=/&>J`1:;J+,(C<DO)=Z=<SQ;X/#GC^*RMFEM]4LXHM)\76%M]ON
M=*:73;O3]`_:'X6_%'P=\7O!&A>/?`^K1:KH6NVHGB*LGVJRN%P+K2]3@4N;
M+5=/F+6U_9NQ>*9&V-)$4E8X/XXI\08K'9%FN"J9'Q=DZ_X5<DKR4DZ3DU#,
M,NQ%HPQN6U7K2KJTDI+VD4I1G.,MS:.,JU<'7I2PF8X:RKX6K?WHNW+7PTVV
MJ]"7\\?A;2FHMGI%%(O3KGN?\]J6OT`]@****`"BBB@`HHHH`*XGQ_X"\'?$
MWP?XG\!>//#^G>*O!_C#0]3\.>)O#NL6T=UIFM:)J]L]GJ.G7D,BD-#<V[LA
M9=LL9"20R1RHCCS7QM\9O'/A0RG1OV9OCG\0Q&8!'_PANJ_L^VPG\WRS+Y7_
M``G7QW\%[?L8=OM`N%A9C%(+47.8Q)^>_P`>O^"CO[5?PMT^_O\`PM_P2@_:
MX\:+:R-;_-KWPTU,O-]CO-0$L=O\#M8^/VI7-@-/@@9KN"P>$:E+-H<KQZFM
MC;W_`'X/+\;C*D%@W1512C*$IXS"8:THN\6IUZ]-1:DDXN^]CNPF`Q>+G!87
MV?.I1E%RQ6&H2BU*+C).M6I\O*VG?[M3\LO$W[97[4?_``1;_:+N_P!DK7=`
MU#]J/]D?4M*L/%?[.DGC'Q#>Z)\1/!/PYU/4);!O!6F>/CI_BB/5H/AU?V>K
M^%AX8\0V-U))I^G^%-2T:]\$:'K46@P_G3XK_;1^/_BS_@H;HG_!1.#0+"QU
MKPC=:=IGA7X2ZAJUWJ?A[2?A?:^&;_PKJGP\3Q#;:9I=T'UJQUOQ/J;^(?[)
M(L_%WB"XU]=%FM;6ST<<Q^TA^V/\>_VWOCS_`,)!^T3X*B^%NH?#JSN/#7A3
MX0KX?UGP_<>`]+U6[&K3C6HO%D<'B34?$NL6[:8VJZM?V6DVEW#9:=_9^@Z-
M:'[++Z38^'M"_L#)CBW>3T*#(4CD@[B."`>/3VKHX\X_P_AW4RR.,R>G6S7.
M,+3RK-J^"C/$T<0L9-0JU+44J,*E:GR3Q%6E%-SYVFN=-_:9OF>&X:6$>,RR
ME5S''X-X',:V&4Z]+$0Q,U&3A*C+V$95*?O5:T()\^BZR/KG_ALC]J7_`(+.
M?M*>"?V+?[`C_9N_9AU.TU#QA\?O#_@CQC<ZQXO\:?##PM-:#7M+UOQ]>>'M
M$EETWQ!<WVB^%K#P]HOA:PT]+WQ!_:GB4>(M/LK>TM/ZXO!?A/PUX"\*^'_!
M7@[0]+\->$O"FCZ=X?\`#/AS1+*WT[1]#T+1[*#3M+TK2]/M8XH+*PL+2VAM
M;6UBC6.WAC6*-0JJ*_S\_`7QK^/W[,GQZ\+_`!)_91L;S6_B_='4/">F^"]*
M\(77CZX^(>C:L]KJ.K>"I_".DP7&O:S;ZC_8UI?O#X=>UUVWGTR&_P!-N[:2
MVW)_4)\`/VK/^"P_BK2-)G^*W_!-?X96@U&"VNAKK?M):!\(PD%Q9R2Q_P!H
M>"=4M/C#XNTFX:;R$N+2]6'4+&27[/=6,,D5R8?<S/#3S7*,GQ^7PRW+LK6%
MYJ>!JX[#X;$/&2L\7B:WUN=.I6G4O",)JK5Y:<53M!:/GS[+G7PF`KX#^SL%
MEL<*IPPD\;AZ.(>(;MB:M58FK"M6G)VC2D^9JFN7W4K'[:;OI^##^N*^:?VS
M\']CW]JO'_1MWQT_]5=XK]_7WJOX,\7_`+5NJ6*3^-/@5\#_``C>/]D8Z=IO
M[2WC'Q7]GAG3S)UEN1^S!H4)N[0L(GBM_M%G)*KB'4GA"S$_;#:X?]C+]J%[
MN*&"Z?\`9F^-SW,-O.]S!#.WPJ\4F:*"YEM[.2XBCD+)'-):6LDJ`.]M`S&)
M?DE3=.O2C*5.356"?LZE.HN][TY26M^_0^)E3<))-Q>J^&I3J+[Z<YK\3^?W
M_@T\`_X8L_:2!X!_:WU(MCC)'P(^!@Y]1CL<C@9Z#']+WQ-\!_#_`.)'@/Q=
MX#^*&@:#XJ^'GBOP]JFB^--`\3P6]SH6J^'KV`IJEMJJ3[(ELS`#++<-)$;1
MXX[N*6&:&.:/^!;_`((O^-?^"Q?ACX`?%2U_X)P?";X3?$'X47'QJN[OQ[JG
MQ`OO`%MJMC\3#\.OAS#=:;91^+?B;X(O_P"S4\(6_A"\5[73+VT^UWMV!?M,
M)K6#]4O'W[)O_!Q7^WQH>K?"K]I#XR_!#]E'X)^)=.FT3QWH'@B[\/3:EXGT
M2_3[/J.G36_PQ7Q=XEU^ROK62:'4_"^I_%CPEX8UFQEEL=7CN;>7)^HSG+(U
M,XQN)GF>6X:+KPFU+$\U>FE"BG^XIQ<U5C:*Y5M*S=E>QRV=[V[?EU]3R+_@
MU5UWQ!;?$+]OCP-X=O\`4M5^#FEM\)-=T62XDGETVTUV?7/BGHVEW]NS&2%=
M1\2^$]*@?4Y(BDU[#X>TW[276VMG'Z=_M??\%]/A+\%/C-?_`++_`.RU\"_B
M1^W#^TII6OS^&M6\$_"DW-OX4TW7-+6\'B3PY!XFT/0O'GB;Q-XL\,R6C)K6
MD^$_A_K&C:;/#J>G:KXHTS5M'O[&/0\>?LZ?#G_@BE_P2'_:@?\`9ZFUJ_\`
M'VE?#O6=3UGXJZE,EOXM\4?&'X@C3/AIX=\=R1P^?9Z'I_@S4?$.D3^%_#&E
M?Z)I>F:/&MQ=ZGKVHZ[XAU?S;_@VE_9@^'WPU_8$\/?M%Q>'[23XL?M(^*_'
MVI^(_%EZ@N=<M?!_@'X@>)_AUX5\'V-Z^7M-"1_"NH>*YK6-GEO=6\2W4FHW
M-X+#3H;",=5P.,JYCGU2A4K89XFC@\'AU4]D\36C0BY5L1**4H1Y(\[C!J4K
MJ\M&#MK+=/3M;3>_R["?"O\`X.!X?#WQ$\+_``T_X*%_L3_'7_@GY=?$"_@L
M/`OCKXB6/BS6?A[?"2X@M;J\\1:AXH^'7PNU[1-*T^YN[*&^UO1=!\7Z-I`N
MX[_Q3?>&-(BNM2@^7/V>_P!JO]F3]H]_CY^V_P#"?]BS]L;]I?XK?!CXW?#V
MPU/P):^+M)^*7B'QEJ?CZ/Q6VF>+]+\.>'=*N(8/"/P^M/"5HMGI<ROI&CVA
M\.V>GV\>G:3!;P_T@?M=?LP_#7]K[X`?$KX!?%'0],UCP_X^\-:AIEA=W]HM
MU<^%?%'V:9O"WC31)?EEL==\*:Y]CUK3+N"17$MJUO+YEI<W5M<?S3?\&F5M
M):_#G]MN&=8_M,/Q`^#=M,8V#1%H-`\?`A&!8,H<R%6[A@>:Y51RK&95C\;'
M`2IU\)5P/-AI8BK/#.$ZZ7/'F:JQE4Y90E&<JD8V4X23;$K<MUK:UUWU7?MY
M'YZ?!K]M?XH>&_\`@NU\??VJ+#]B/]I?Q+\0/%'@[5M*U#]D_1?#-Q-\<_",
M,WPO^#^@/J>OZ$NGR7%O9V^G^'K'7)F;34"Z;KFC2*XCN`R_UW^!_P!HSQE^
MT_\`L5_'?XD>.OV<?C%^RYK4/@WXR^&E^&?QQT6;0?&L]CI7@"XN+;Q1'8S6
MMF_]B:LVI2V]C-Y)#SZ=>+O/EG'X%_LR#/\`P=5?M=^@\`>)>.>@^"'P%'KU
MK^I[]HG_`)(%\</^R0?$K_U"M>K3.:U"=?+*<<)&E-8'+7&LJM9R4'3IM4N2
M524.76R=N9V>NHI:M>B^1_%Y_P`$7/\`@JE\'_V#/V#/$GPO_P"$'\??M`_M
M-?%G]K#XB7_PJ_9T^$.F/JWC+Q'`_P`)?@9I6F:KK<L,5]=^'O#^K:QINIZ7
MIESI^A>)_$6L7.EZPV@>%=7M]$UF:P_2&S_X.-/'?PC^(WA+PU^WE_P39^/G
M['_@7QJTRZ1XYUB^\7:WJ$:P7%M;W%]%X1\;_"'X32^(](TG[9;2^(+CPOK6
MIZUID4L7V;PWJ=U/#9MX_P#\&IW[-_P_3X*_M`?M6WNF6&I?$_4_BQ/\"="U
M6\L+*XO/"7@SPEX+\$>-M6AT'4'A:\LI/&>K^/;-?$JP3)!?P>#?#(:'-HYE
M_6'_`(+Q?#WPMXW_`."6'[5$_B32-/U*\\%>&O#7COPK?W5E;7-]X>\3>'O'
M'AIK75=%N;B)Y=,O9].N=3T*[NK-X;B;1-9U;37E:TO[J&?MS&>5RS^O@JV`
MG7>(QD*5?%QQ%6G4IU*KIQ_<4U^Y4:?-9QJ0FYRBVIQOI4K<UK;V5_6UG\OQ
M/4_V\_\`@I?X$_8C_9D^'W[65GX#U7X^_"3XA>(_!^C6&L?#?Q'H]M!#HOC_
M`,+ZMXH\(^-8=0U-#INH>%]7M],ALX[N&ZB?[7K6B^4L\=V[0_;GP-^+_A']
MH#X.?"_XW>`K@W?@SXL>`?"OQ"\,R2A1<)I/BW1K36K2UOD5Y%M]2LH[L66J
M69<RV.H6]S:3!9864?SV_P#!/CX(:Q^WM_P;G>'_`(!^)+VQU;Q+XN^'OQW\
M$?#[4_$C7-Q8Z/XH^&?QT^(LOP2GNY%>2Y@TKPAK'A;P;9(MON,.B:4MI'$\
M/^CGI_\`@V?_`&F+KXG?L/\`B7]GSQ3=PKX\_91^(^J^$1HCI<1ZW9_#OQY=
MZGXN\(S:Q'.-JRVWBYOB3X3LUA9!9Z5X4TZVN(8&C$L_CXO+Z-+"8U4W-XK+
MLRGAJ\V[JIAIODHU5!:0<:L90GKJY*RM:\-+H[_)GMG_``5\_P""J'[.'[$-
MQX*^`7QL^#OBWXVGXV>"?$7B+6-&\(:YH&BWOA+P]IVM6>CZ!J\CZQ*MVE[K
M&L0Z^_AV^T]8I-/OO"=W/'<+,8L?H_\`LM?`?X-_##PK;>-_@AXE\3ZMX(^*
M6@>'_%NG+=>)TUSPQK.G:I86VJ:#XHTJ".VC@2XU'1KJVQJ-I(!J.G26L=W]
MICL]/-I_)SJ'[.5__P`%K/VP_P#@KQ\>+2RL=1\(_!/X2ZM^SC^RHFIWK:C;
M3?%CP;=E_AYK_A[5X9%LK#0->O?AMXQ\1Z[`C!['2_CO:A?-1;B2X_9+_@WT
M_:DMOC-_P3)\%:9XGU&SL=6_9:U'Q-\%/$U[>WT$2VGA/PE9V?BKP1J]S'(T
M;:9HVE_#SQ#HOAX7%TPAFN/".JS+,JPR10>?F_!_#LY9;GW]FX:KQ+E$:>$Q
M>-G3C+%8>EF5.4Z='#U;<\*:3E1K134)2E*,E):K*I@\-4K4L7*A3>*I1Y(5
MW%*I&$DN:"EI[K=O=VOTN?27Q'_X*J_#OP7_`,%&OAG_`,$V?"_PU\5?$3XI
M>.=+TG5?$GBW1-3TJS\+_#47OAWQ-X\U*P\1V]R'U.YO]'^''AV'QE.+2-;:
M6U\0:'8QW(O)KI+6S_P43_X*[?LM?\$X+/2]$^)UYK7CWXR>)]'DUOPG\$OA
M['IU[XPN=)DEU"QT[Q+XJN-0U&RT_P`%>#=0UC3KG2;;6M2:ZU35)[/5SX4\
M.>*9=!UJVL?R(_X(1:1JO[8'[;G_``4+_P""IWBN6XOK#Q=XZUCX,_"&2ZL1
M#';>'-3O-$\2&S$DL8,=WX)^%?A[X,>%;::UD66ZMM4UK[6=[K`/,?\`@D+X
M-\)_M[?\%>O^"A_[;/Q7CE\<WGP+\?&S^"&D>*X;?4K+PW;^*?&/CSPE\-M=
MBMKB%H8-6^'?PQ^%EMH?AQ4B$5AJ&NWNO&)?$-G8ZE![DLLP5"K6=:%5TLJP
M&&GCZ=.JHSQ.8XAI>PC)QFJ5-3FXMQBW%4W=J;-[6U[<MU]W7_ASZ7M?^#@K
M]I#P%;V'Q#_:=_X)#_M2?!+]G>=[.76/B_:R^-M:C\.Z;JK;-'OYK3QQ\%/A
M7X3O$U"2>P2(7GC[08IS=`:?/?S-;077V3\"?^"Y/[-W[3'[:7PQ_9`^!_AK
M7O'=O\5?!5QXRT/XPV.K:3;>&--:P^%6M?$[5O#/B#PU<$>)]'\3:&^A7O@_
M7-+O+>.YTOQ$CQW,0BA._P#:/4=,L-4TR\TK4[.VU#3=0M)K*^TZ^@BN[*\L
M[F-H;FSN[6X26&YM;F%VAN+::.2&:)GBD1XV*G^)G]F;]F?P%^R5_P`'/$/P
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M_!Q+\*_%G[+_`.TI^QM_P51^#NGW4/B#P3XV\,^`_B$NE6[Z?;:AK_@>^O?&
M_P`.;SQ'JVG6[2+9^-?#:>./ACXHOM9$L4_AVQ\,^%X!,MY#85_1[\4?VROA
M7\/?V(?$'[<,=Q>:O\++#X$67QR\-QE(;#6/$VF:_P"&;'Q!X*\.017,R06/
MB+Q;>ZKHOART@NKB&&UUK58(+NX@5))$X<9@H/#97BL%"3CCJ7L)T[N;CF%&
MJJ=6'E&ISTI4XWNTY6;1+6UG>_YGY4?M?_\`!P+X(_9I_:G^)'[*OP]_9@^(
M7[1GBCX46VDCQGK_`(+\7:3H>GV6LWNFZ9J>K:/9V-QHFM37T?AH:[HNDZQJ
MHN8(H?$<VI:&;1)=)DGN2OE3_@VF_9W\8>.+#]IS_@I!\:+JXU_XA_M(^._$
MW@WPSXBUC28(;O5]/@\5OXU^,OC"QNF@BM)],\<?%&ZL-$:STV&WLM*U+X5W
MUI'&!MMK(KIQ\<KR_$RP4<%/$SP\:5.O6>(JQY\2J</K/+%5(I1C6=2$4E:T
M=-+7JT5H]UOIZ/M_2/ZQ6C1A@QQGIP5!''3MU&3CT_&H'C15;*#'3A0/;CCU
M.0>W6K3,%!8\`=:^,_VF_'_Q8UF>']G7]FVXM=.^-WQ"T"74=3^)FJ:<-4\+
M?LY_#6_N[C1YOBWXFTTWEB=?\3:I>66LZ'\'?`<%U#<^-O%VE:QJMR]OX*\`
M>/\`4](\2C1=:I&DIQII_%.II3A"+3G.=OLQ2OHG)NT8)RE&+5.FZLXP4HP3
M>LYM\D(Z<U23O\,(KFDDI2:5H)U'%/\`FJ_X*_\`CWQ)^UW_`,%!_!G[/O[)
M'PGO_C!X_P#@/X"O_#_Q.U_X?VEKJES)K>L:[#J-WX8\2:W&(M$T?0/AD8K&
MTN=3\0Z_96>D>+_&OBGPW=II6JZ?=17_`.8_C76?BM\+?B9/^SUX_P#!'B+P
MU\:(-<T'PG_PKBXBM;W7KKQ!XI33!X9TO2CI5Q?Z;K,GB`:UI+Z%=:1?WUCJ
MJZE8/87,\<Z,?[MOV6/V1_@Y^R%\/&\`_"?2-0\[5M4D\1^/O'7B?4#X@^(O
MQ2\;WL075_'/Q#\630076O\`B/5YA)/,ZQVFEV/F&TT;3-,T]8[1/RZ_:_\`
MV?[#6_\`@M%_P3%^+LVEV^I6>M^"_COH^M0W=K;S6FGWGP+\&>)_&WA#5D67
M:7U%-?\`BE#+9S$RS65QI5O?6<0>SGN(/KZ=;AO.*F'R_%Y53JX3*,LQE7"X
MJLW];Q.*PE*KC>>I&5J=&&)E3J0A2CSSIP4(^UDTZ;^XP6;977G#`5,#">!R
M_+\54H8FK*2Q5?$8>A4Q'-).;A2A5<&X4TI.$6HN;W/P3\+:M^UW_P`$C?VL
M/@S^T7^TC^SEKEC\.]9&M^%]2%MJG@[Q5!K/A[Q!IRVNNV?AOQ-X6\0:[H6@
M_$/1;62/7-'\/^(;_1+OQ);6&H:0)[31;C5=8TK^V_X&?''X5?M&_#'PM\7_
M`(.^+M*\;^`?%]G]NT?6].\P$,K&"[T[4[*XB@U#1]<TR[673]9T/5+6RU32
MM0AFL[ZSAGC9!?\`B[\'/AI\>?AKXI^$GQ<\'Z5XY^'OC33UT[Q'X9UJ.5K.
M^BBNH+^SN$EMI(+JRU/3-2MK35=*U73I[74](U:TM-3TR[M+VVMYX_YI=0_8
M'_;]_P""2GQ2\1?&S_@GKJNH?M)_LR:OJ$&L>/\`]F3Q'/-?>-/^$?LS8MJ%
MK'HEM+:1^*_$MM86US8^$OB+\/[:'Q[IZR:=INM_#SQUHFFZE:^(:]IE'$^"
MP^':PF19]@J/L,+>]++,TP_-S1P]2O-R6#QD9S;A5JR]A67QU(KE4.2IB,OX
MFH485GALJSK#4_98>]24,NQ]&$FU152;FL+B8RDU&567LZC=I5(^ZC^JHJAY
MVQY&.`H_D002`<<=*^;?VSR%_8\_:J)PH'[-WQS]`!GX7>*@/89R`/<X'I7R
M/^R+_P`%<OV4/VJ%/A74?$G_``H+XX:7J$.@>*?@;\;;NP\&^,+#Q2;B>QGT
M3P]=ZI-8V'BZX6^M9XHK'3!#XHAB>R;7_"OAV[OH;%?TA\;^#_#7Q+\#^+?A
M]XMMGU'PIXY\,:[X/\36$%Y=:?)?Z!XETF[T;6+2*^T^>WOK-[G3[VXCCNK*
MX@NK<L)H)HY$1Q\KB,)B\NQ,*6-P]:A.G.,N6I"R:36M.=W3JPDGS1J4YRA*
M+C*,FFCYC%83%8*K[+%4:M&I'I4347:VL'K"<7O&=.4X2C9J6I_,;_P:>8_X
M8M_:1W#_`)NWU0<C^[\"_@<I'3L=W_CQZ`FOZGM@`Z(N,GA1^/\`7/K7R%^Q
M]^PY^S1^P7X%\4?#;]F/P7J'@?PAXR\8R_$#7M-U+QEXO\;2W?BB;P_X?\+R
M7Z:CXTUO7M0M(CHWAG1;465K=168:W:?R!/<SR2<E^TC_P`%$OV8OV:TN]*\
M2^/;3Q=\0D>[LK'X9_#T1>*_%\VKVPC5-+U6.QN?[*\*7%S/<6\,"^+-1T5[
MP&8Z;'?2PR0IKF5=9GF>*Q.%IU)4ZU9SIQ<5S12ITXKFM>,7S1FVV[)VL]S*
M$*E67+3C*4F]DF]^_;1=>WD=G^W?\#=&_:>_8^_:"^`&J:AIVF-\5/AMK_A;
MP_JFK7BZ?INF^.);<7GP]U&\NY%*I!8>.K3PY>-$H+78A%K&KF<(WX._\&_7
M[=?PL^%GP+NO^"<O[2OB32_@/^T=^SK\3?B/X<T;P7\4-8TSPT_BNP\2^-/$
M'C'5-#T/5;^>UTR]\8>%O&&L^*=*U#PQ#=37MWHR:+K.@MJUC)J0TGV?Q7\%
M/V^/^"I?B32+WXNV5[^RA^R=9ZG'J6E>`M02\'BS68;2>#-Y<>'+D:7K'B'Q
M-/B1=*\1^-=-\->%-`C*ZMX8\-ZK(]Y)K7WE^TU_P1^_89_;!TWPW<?'KX::
MKXL^)'AOPSX?\)K\=K+Q3JGAOXT^(]/\-Z=;Z39W/CKQ?H+:?;^/M1EMK<M-
M<^,-'UJ&&:>XETNWTY9$2/HHU,-0PD\NQ]2<Z5:K#%<^&Y)U,)BH1=.+Y9-0
MJJK3DX3491:LN6[L:5*<:2C"4TYW;G&+OR/31O5.R>MKZ]3C/^"HO_!4CX"_
ML7?L]^/#HGQ+\+>*?VC/&/A#5]`^"GPL\):YIGB#QA=>,-?M)M(T'Q9J^CZ=
M->3Z/X/\,WUT->U'5=8CLK75XM)FT#1);[7;ZSLV_(#_`(-+4:'X9?MK12"1
M'B\??!F-EG#"8-'X:\<HPE#@/Y@*D/N&2V6/4FOU_P#V5/\`@AY_P3J_9'\9
MZ;\2/`?P;N?&OQ$T&^M-2\->-/C!XCO_`(AWWA?4-/FBN=/U/PUH>H):^#=&
MUO3KN&.\TSQ%:>&E\1Z5=1I+INKVNQ`/JG]D+]@/]ES]A6R^(.G_`+-'@;5/
M!%M\4]8TK7O&J:EXW\:^,VU74]$BU.'39XI/&6O:[)IR6\6L7ZF#3FM()1*I
MEC=HT8;/'99A\KQ^7X2.+JU<74PL_K5:$*:E[*M"<H2I0J5/9PA%-T[SE*3G
M*Z22OC>*32OK8_F^^%FKZ+\)/^#J;]H.?XB:OI_A"U^(?@6\M_"%_P"(+NVT
MO3]>N?$G[/GP@U+2+:PO;R2"VFFO?^$7UVQM8UD9[C5-.GTR`-?;H7_J"^,7
MC?P9XV^`/[1+>#?%OAKQ:OAWX<?$[P[X@;PUKNF:ZNA:_%\.[W59="U@Z9=7
M0TS6(]+U?2M1DTR],%ZMAJ=A>-`+>\MY)/E_]N+_`(),?L8?\%`]:\/^,/CY
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M^"VG_**W]M+_`+)3%^?_``E_AC'XYZ#J3P.:^HOV0_V+?V=_V%OASK?PE_9I
M\':AX(\#>(/&FH_$'5=)U'Q;XK\92W'BG5=#\.^';Z_74_&.LZYJD$<NE>%M
M%@%C#=I8QR6TMS';K<75S)+Z?\>?@7\-?VEOA%XY^!?Q@T2Y\1_#3XCZ0NA^
M+M$M-9U?P_<ZCIBWMIJ`@BUG0+W3=9T]OM5C;O\`:-.OK6X`0JLH#',XK'TZ
MV<SS*$9>R>-IXI0DDI\L*D)\K5[7?+;<&];^GX6/R5_X-U`#_P`$B?V=$/!/
MB?\`:*'/8']HGXJ@>G3(&`0005X92!^`G[7_`,8_%_\`P1B_X*?_`+?M]X+T
MEX_!7[;G[.'C;QG\*X]"N%L3X;^('Q2DOK_PUXWD146&`^`/C9IGQ.6+3(BR
M0>$M922R6":>"./^T+]F3]F/X-_L?_!GPO\``#X"^';WPG\+_!MSXDO=`T*_
M\0Z_XINK2X\6>)M6\7Z[))K?B?4=6UFZ%UKVN:E=1QW-]+'9Q3)9V:06<%O!
M%XE^U]_P38_8V_;MUGX>^(/VGOA0?'^L?#*#6K/PC?VGBWQEX0GAT[Q!=:1>
MZGI6K/X.UW0_^$@TN2ZT6RFMK#7/M]O8/)J!L4M_[4U'[3T8;-L+'-<?BL12
MJU<#F#K2J48JTY1=?ZQ0ZV4HU%#F?2/-:^B"+2>VGX]/U7;0^8_^"&'[*C?L
MI_\`!.+X(:-K%CI]OX[^,-C+\?\`Q[-9I.)7OOB=:V&H^$-/OVNU6X75O#?P
MQM/`WAK6H&410ZWI.I>2\P+33?RX_M@?%GQ7_P`$D?VI/^"P/[-OA;0+?3O!
M?[<_PFLM;^$RP"6'0M$L?BKXI9]1N=,L;62*+1[#PAX'^)7[17A'1)XX"J>)
M_!'A2W99=)`\O_0/MK6WM((K:UABM[:WBC@@@@CCAAA@BC2**&*.-52.**.-
M4CC0*B(`JJ%50/A3]I;_`()G_L7_`+7?Q@^''QW^/_PAC\;?$_X66NB:=X3\
M0)XK\8Z!$VD>'/$LWB_1M%\1:-X>UW3-$\6:-8:_=ZE>1Z9XDT_4K22+6-7L
MIXY;+4+BV=8#-Z-',,9BL=2E7HX_FG6I0L[U8UEB</))O54ZD>1ZJU*<]=$$
M96=]]+'-_P#!*+]ED?L?_L#?L[_!C4;1K?QC%X*M_'7Q(%Q9QVE]'\1OB5-+
MXW\6:5>[$5[AO"U]K2^#+.YN!]JFTCPWIHG5"@C7^?[]FCXH^%/^".'_``61
M_;(^$W[1_P#9GPL_9T_;;U:?XG?"?XOZD+VP\`:%#<>-/%?C+P78W^JR6PL=
M)\-:!+X]\=?#/Q7J=V88/#/B31O#FH:M-8^$-4D\20_V*)&J+M7/;DX)X_`=
M\G';)`P,`?)?[8O[)7P0_:X^$M_X%^,_P2\$_&V/3%N]1\)Z3XLU35/"=]I.
MM3VK6LMUX:^(GANSN?%W@74;RT9[.74_#[QM<1,MI?K)I[S*G%3S6%&68U<=
M"M7PV/A4EBXX=.IB.;G5>%3#TK2]K5C.+<:>CG=PC:]Q2G92;3:W:BKR=ND5
MNY/HE=MZ)7=C3^+'[:?[*?P4^%EU\8OB1^T!\*M"^'<-@+ZS\1+XST35H_$(
MEA\^SL_"5IHU[?7_`(OU;4DP-,TGPW;:GJ&I.=MI;2@.5_B[_P"";W[4>J?M
MH?\`!Q/HO[36H:7J&AZ7\4K[XXW?@G1]5M(+*_TOX<>&/V>O''@7X>V=];VE
MW?V(U:+PAX7T?_A(I=-O[[3I_$SZW+:WDZ,SG]/?V?/^"0__``28\,?%==%^
M._P,^)GPY^)FFZI+<:5\*_CG\9=>UKX6^(XX-0AM+&[\-^)M+MO!MAX]L3<S
M6\*:1XAU+4[75))7B^Q>(;)994_;KPQ_P3>_8V\*?M,>&/VO_"7PHM_#'QN\
M%^$;'P!X2U3PYXE\2Z)X-\.^#=-^'Q^%VF^'-&^&FE:Q;?#S3=+L?!+C1K&T
ML_#<<=KLBNH-EY&DXSX>XHX3Q>#S&IDN+Q.8U,3@L3@*KQ%"."Q.`KSLOJ^*
MR^K4>+P]2,DXU5B%3FERN%*1GAL7AL1!RH55-)M37PU*<EO"K2DHU*4X[.%2
M,9)IZ'4_\%`/V6=&_;-_9`^.W[.6IQQ)>_$'P/J(\'WTMT]A!H_Q)\/M#XE^
M&FNW=U"K3+8:/X\T?P]?:K;J"FH:5!>Z;<K):7<\;_P`/^VA\>?BK_P3_P#@
M?_P1KT/P5XT_X71;_M=:EX)O].U34)+34+OPJGBNPO/AQ\(=<BUB9$M]0L?C
MSXS\1BZL[J^L-!\#:+\)_!\#2Q:?=LNA_P"B]\>OCW\)/V</AQKWQ5^,_CG0
MO`G@KP[97=W=ZCK5W%'/?R6]I/=#1_#^FA_M_B+Q)J$4,L.D>'=&M[W6=7NS
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M&"3EO7.`!GU(4*._``SQ17S$YSJ2E4J2YIS;E.3^U*3O)ZZZN[UU);N[B21^
M8A0DC((R`#C((Z'(/7H01ZBN3\->!_"_@^?Q%=>'=*M--O/%OB&]\4^)[]/-
MEU'7M>OEB@?4=7U&YFGOM0EM-/MK#0](CNKB2WT/PWI&B>&M&AL-!T32M.L^
MPI,#T'Y5+UTNTGNEU6]G]P@]?<_T`KY#^+O@G3]8_:E_9(\8ZA:Q7%SX*L_C
M^FBSM<W44UGJGB3P5X;L9Y8[>*5+6ZAGT6SU>VE%TLWV>:>">"+<9)X/KVL3
M4?#^DZGJ6C:O>:?;7&I^'YKN?1KZ2)3=:<]_:M8W_P!EFXDC2\LW,%Q&&\N9
M0AD1C%'MTHU/8S<TM72K4]--*M*=+[ESW:ZI6-:51TI.2UO3JPZ?\O*4Z=]G
MMSW:ZVL:L7'R]L<9.2<=\^XYI[J&!SGH1Q]*4``#C!_,_G3JR2M==/\`@)?H
M9'SI\9_V4/V;?VA[9K?XV_!'X9?$MS"8(-3\5>$-'U'Q#8QLH0_V5XG-LGB+
M1W*`)YFEZI92HH`1P.*\>\/_`/!/;X`>!9+&3X;:I\>/A?9::0MKHG@#]IK]
MH/1/#0BC>W>*W?PPWQ)N_#QM(5M(8(K)--2S^SJ+=X)(4ABB^ZRH/:LS5D=M
M-O(XTNW=[>X54T^:*WOY-T,@\NSGGGM(8+M^$MYIKF".&8QRO-&J%AT1Q>*A
M"%*.)KJG=1C1=6<J,;I7:A)N*=D[6BE>RM>UNB.*Q4(\D<165/;V?/)PM9+X
M92:^222['Q???L#_``)\1VTEIXXUSX_?$G3GC6*32OB%^U#^T1XGTLH"S,)=
M-N?B6MA<K(2C$7-M-&&@BEA5)#-)+Z[\(_V6?V>/@;"B?";X/^`_!-W;L[#5
M]+T"SG\2R>;YF1<^*+X7?B*[0"61(TN=4ECB1FCA"QX%?FUIMC^WQ\-[+X>6
M/PWT/QQ=Z1=6OP_\.ZKI&KWG[/,=G:>&K#Q]^T"VH^-_$FFZI\0_$<\7C3Q-
MX1?X7>+/BIJWA7Q7X@O_`!#XC\5>;X9T^TBTV_\`"/@N+X(W?_!0C0;CQ_X<
MU>Z@A^+?CKX)>//B_9:%\01\)I=(M?C[X;^'GAGP/H-C>7'PTGO=-@^'WQ$^
M*/BRWO;6VTW55NO#7AGX(6O]L/:W_CW6I_$OH3PN(E2E4>84Y4XP4E#ZQ47-
M'W^=>SM9<D::=K\KYHI,F>)KN-I5JCCHG%3:C;1+W(M15M-EI\C]IA.B'9@+
MC/?@A>^0#C!^\#TR#_$N;".KC*G/T_SGZY`(Z&ORLT3X8?M3>)?!WCSQKJFL
MZYHWQD\5:AX!TOPKK?C?3O@_JM[H?PT\(_$7Q]J>FVNK6/PKU;PE87%Y?^!-
M3T;4?%^CV7C1M%D\9ZMJU]X;M8;9)-./`_`73?\`@HM'X2\&^!_B#J_B_P`$
MVOA-?@[H%QXDTFZ_9O\`$.H:MH$OC7QXOBT)?ZQ;>-[W4+O1?A)>_#2VU+4M
M7TBRU?4/%&AWUWI-WK\]UJ]]K>/]GWC)QQ>%DX2M).I;[,9/E:BW))MQV3NG
M?I?GYDM](Z6>KOM\[^I^RE51=)CG:.1D;^0"2,X(!ZJV.,MM)`(&:_&;P[XJ
M_P""HVL^(?!AUK3M5\,:38VW[,USXVM3=_LRZE9ZQK5SJS0?M`:;9W%F;K5[
M?PI>^&8=-UU8+5-.\2Z5J^K:OIG@GQ/J5M:Z=Y%;Q-\%OVO+OXI>$-1TNV\7
M'4?#?QT^.?B'XG>((O'WA*+0_BS\(OB!^UE\(=>^#OA_3#)XSMM=TU?A5^SN
M]VT&G:EX8T9]/U'X;ZM\/]+FU'3_`!LFM^(".7VJ1A6Q5"ES1NI*3G!7BVN:
M5HI+F4(.5VHNI%R<8IM.^S2;O_FO\_P/VD%PAQRN#T(;(/3@?*`2=RX`)/S<
MX&"9\\9'/ICG-?C+XI^%O[4S?LW?#;0OAQH/Q`'Q4\.>%/VE?!/A:[UOQUX!
MTK4[O0?%'A?4=/\``'QE^)&O6'Q&U*VTG]IG[1:Z'K6A^-O!MSXWTG4-9UCX
MDVWB"V^%=G\2_P"T?AUT<+_\%%-:EOO)\;>,O#]M!=?%":SM+?1/V7/M26G_
M``MWX0V/PEMGU>]M/%4>IQS?`'7?''BK6B^BZ#=VGQ)T;6K:ZO-1T2\\&>&G
MF.!4HW^MX:+4I1:J.HI/EYK32ITZK<96TD[1YGRMJ2L-7?1_A^ES];VN57(.
MW<,<%P,%N@)P0,]B,C/&>1D-RH&<'&<=^^0IX!X9AM!]>N!S7YJ>,-._:?M?
M'=UK'AOPKXBTWQGXIUCX=7,WQ(T^X^%OBWPQX/\`A@?A;X?T;Q/\--&\'>-O
MBAHMU!J,?[0MH?$OC-]#TO3O^$@^'FKRR:#\1;WQ1I^DZ?HOS7:?L_\`[56@
M?![X-/X>T+6=*^*W@_XQ3^(6NCXQ\!:M<Z3H,/\`P3^U+P1IU[<C7M>U/PIX
MAMK/]H31?!SQZ)J5MJ]M)XAT;2_%]UI$^C:<-8"C@5*W-BZ$&W"R=W&\HN6L
ME%[2BUI>6E^5>ZFF[>G==M+Z;Z7?W/4_<96W#/3GUS]/S'-,>4*0."23U(&,
M#/0\GG`^4'&<U^2_B'5O^"A%W<>,+G0]:\7^%=(TOQC\2M(T.:[TK]F/Q7?_
M`/")GX6V\6@^(9-/%WX<M/$$_AGXFQ:EJ/A6UEU#X?WFKVT,-CX[T^;2)FE/
MB-UXP_X*'>-KG7OB'X<\,>+-5NO"5MXN\$^#K*+Q3^S99:OX5^)T_P`9/%G@
M+Q_::'-?Z;I?A;QGX?\``O@/2?!4J7/C[0=.F\7>*-(\<IX=OO#>FZ]X=OK"
MXY;5E'F]OA=%%R7M6G%S;C&-YPA%MM:VD[+5VNDRZT\]OZ^9^[.X<9X.,XZX
MXR>1Z4F]"=NX9')]O3MC]:_%O0=3_P""CZ7,'B_QW<>/[N<S_&*ULO"G@[6?
MV9M+T_1(O$'QK^*&E>";O[-J5M/INOZ9X*^`O@KP%XPT*R\17FK>(M0\7^(-
M0T37/$-I_:NLQ>$&>`V_X*1:=XQTF]UBT\9G1]5U[P-<^-?M.O?L^ZLEE<^(
MO%WQM\2Z_HNCQWGB"]NK#X4:/IWB#X0Z1X@.GBZ^)FGV5OJ&F?#6:\LM/CDM
MZ>622E_M6%NHMI>TEK)3<>1-QM=I*2UUYHKJ%]E9W:O:WII^*/VE:9$;:2-Q
M&0,C)Y].OY`]_2F?:(SUQC!8Y/8<\\>V<'D>F>*_-F.#]MZ3X1^"(9_$&M?\
M+.<^%(/$OBKR_@>NN6UMK^L_L^7/C"=;&+2E^'4]QH-AJ7QLTG1GA\+W8-EI
M&G/]GU75)]+U?5_!OCAXD_;/\*7'A3Q7X#T'Q)8_%#XI_!CX=>%_%-]83_!#
M4Y/#?Q[D\+7%]:>`_A;!X]\6:OX77P9XB\0P>(-4^(S>)M-TG3-*D\"6UWX+
M\5Z[=^,W2TR6!<G&*Q&&O.4XI^T]Q>SM=RDX^[&4=8MKWM%9-H3=NCEW2U?_
M``_8_6/Q]\./`/Q0T*?0/'GA70?%^BSEB;#7-/@O4@=E"&XLYG43V5RJYV75
MI+!=QM_JYE(7'QUXH_8&\(S`0_"KXY?M'_`FS2!TC\/?#?XN^)+7PT2[!S.V
MFZK-?:D)7;RUD6TUNR##<H2(N)(_DWPWK'_!4_0;'XO'6-*U/4OM7B#XS:?\
M+=/TG5/V;GMM!@AUCX,ZI\*/$5O+KUP^J:WINNZGKGQB\/:_I'BW7+74K7PQ
M8V%W;1^&-:L-`EU[Z,\?>'OCGX7U/1M9T#PQXMUI++P5X:LO#.L:#K'PSNY?
MA?=6?Q9\4:Q\>-832?B'XNM-"U'QIX\^!6K:5HWPPOG\-^,=&TS7O#EWIWB=
M_#6DZA,FM>1CN#\FQ>(IXW&8;+JV.I2Y:.-HIQQJ46H\OUFDZ>)5-7^"55P<
M7?D::YL98;#5JL:SH0=6+7+5<(PK)VTBYQ2FU;HY.-^E[GS%X@_X(7?`3XD>
M,-)\3_'?X[?M$?&:QTNXAG.A>*/&4&W5X0Z^?I>K^(+JRU7Q8FEWL:Q02)X?
MU[P]J"JBFWU&%UCV?K]\)_A3\-?@=X#\,_"_X3>$/#_@'P#X3L!8>'O"WANQ
MBT_2["V#-)/-LCS)=ZA?7<\]]JVJWTESJNM:I=7FJZO>7NIWEW>3?F5HOA+]
MO#Q)\9/V;-7^+\FNZGX7T#7/%GC/Q7::)J?P3TOP=X3\3R?!_P#;(^&&L6$I
MT6;2_B)K6FN_B/\`9VO_``'!;S>)K>/4/%WQ'U7QA+`VA^%;/P9QWP=UC]O'
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2-5E9I/E;5XI[IK9;.VE@/__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
